{"id":154869,"date":"2026-11-19T15:04:13","date_gmt":"2026-11-19T06:04:13","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4892-20261119-01_wp_product_announcement\/"},"modified":"2026-11-19T15:04:13","modified_gmt":"2026-11-19T06:04:13","slug":"4892-20261119-01_wp_product_announcement","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/","title":{"rendered":"Notice Regarding Progress in Development of New 3D Cellular Products and Recognition of Non-Operating Income"},"content":{"rendered":"<p>Upon completion of the publicly funded project, 15,000 thousand yen will be recognized as non-operating income. Going forward, the Company will promote practical application and commercialization of FCD products and aim to expand offerings including 3D mini-intestinal models.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4892","jir_company_name":"Cyfuse Biomedical K.K.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4892-20261119-01.pdf","jir_short_summary":"Upon completion of the publicly funded project, 15,000 thousand yen will be recognized as non-operating income. Going forward, the Company will promote practical application and commercialization of FCD products and aim to expand offerings including 3D mini-intestinal models.","jir_summary":"### Overview and Outcomes of the Project\nThis project was conducted as part of the Tokyo Metropolitan Small and Medium Enterprise Support Center public solicitation program \"FY2024 New Product\/New Technology Development Subsidy Program\" and advanced development of FCD products with the objective of enhancing drug efficacy evaluation for organ fibrosis diseases through the development of a three-dimensional extracellular matrix (3D extracellular matrix). We report completion of the project and establishment of the associated technologies and knowledge.\n\n### Future Outlook and Business Strategy\nWe are already selling a human 3D mini-liver model that reproduces liver fibrosis and are expanding its use in drug discovery research. Going forward, we will pursue practical application and commercialization of FCD products and promote expansion of the product lineup combining human 3D mini-liver (healthy and disease models) with 3D mini-intestinal models. We also indicate potential applications of the extracellular matrix in oncology for drug efficacy evaluation and novel therapeutic development.","jir_financial_highlights":"Non-operating income: 1,500 thousand yen (Recognized following receipt of the confirmation notice)\nGrant amount: 15,000 thousand yen (Stated in the confirmation notice)","jir_category":"","jir_hashtags":"#CYFUSE, #NewProductDevelopment, #BusinessProgress","jir_key_figures":"Amount of non-operating income recognized: Unknown (not stated in the text)\nGrant amount: 15,000 thousand yen\nDate confirmation notice received: Unknown","jir_meta_title":"Cyfuse Biomedical K.K. \u2014 Progress in New 3D Cellular Product Development and Recognition of Non-Operating Income | November 2026","jir_meta_description":"Cyfuse Biomedical K.K. announces progress in developing new 3D cellular products and will recognize non-operating income upon completion of a publicly funded project. The release outlines plans for practical application and commercialization of FCD products and expansion of the product lineup.","jir_og_title":"Cyfuse Biomedical K.K. Announces Progress in New 3D Cellular Product Development and Recognition of Non-Operating Income","jir_og_description":"Cyfuse Biomedical K.K. reports technological progress and project completion, and introduces measures aimed at expanding product lines and applying the technology to drug discovery research.","jir_og_image_url":"\/assets\/og\/company-product_announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":59821,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-154869","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notice Regarding Progress in Development of New 3D Cellular Products and Recognition of Non-Operating Income - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/\",\"name\":\"Notice Regarding Progress in Development of New 3D Cellular Products and Recognition of Non-Operating Income - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-19T06:04:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice Regarding Progress in Development of New 3D Cellular Products and Recognition of Non-Operating Income\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice Regarding Progress in Development of New 3D Cellular Products and Recognition of Non-Operating Income - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/","url":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/","name":"Notice Regarding Progress in Development of New 3D Cellular Products and Recognition of Non-Operating Income - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-19T06:04:13+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4892\/ir\/4892-20261119-01_wp_product_announcement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notice Regarding Progress in Development of New 3D Cellular Products and Recognition of Non-Operating Income"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"59821","title":"CYFUSE BIOMEDICAL K K","ticker":"4892"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=154869"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154869\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=154869"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=154869"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=154869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}